Alimera Sciences

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Alimera Sciences excels in Q1 2024, eyes revenue growth and market expansion

Alimera Sciences' Q1 2024 performance reflects robust revenue growth, profitability improvements, and strategic initiatives to drive product awareness and clinical advancements.
While facing challenges in margin stabilization and cost management, the company is well-positioned to capitalize on opportunities like indication expansion and sales optimization.
Overall, Alimera Sciences' strong financial performance, focus on innovation, and market expansion efforts position it for continued growth and success in the ophthalmic pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alimera Sciences is a pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. The company is passionate about protecting the retina and developing innovative treatments to preserve vision.

ATLANTA, April  13, 2020  (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces top-line revenue guidance for the quarter ended March 31, 2020.

Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update

Cumberland Pharma

Overseas Shipholding Group

Roadrunner Transportation

Titan Pharma

In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.

Penny Stocks to Buy Using Technical Analysis for April 2020

ATLANTA, March  31, 2020  (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has appointed Steven T. Gill as Vice President, Thought Leader Engagement. Mr. Gill rejoins Alimera from Novartis US where he was Associate Director, Thought Leader Liaison. In this newly created position at Alimera, Mr. Gill will have the responsibility to advocate for Alimera with physician and professional societies, further driving Alimera’s mission to be invaluable to patients, physicians and partners concerned with retinal health. He will focus on leading a team that will improve customer access by building long term relationships with physicians and key opinion leaders.

Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement

ATLANTA, March  25, 2020  (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that nine posters on ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection will be available online during and after the 11th Annual Congress on Controversies in Ophthalmology (COPHy) conference beginning March 27, 2020, a yearly congress held virtually this year due to precautions around the coronavirus. 

Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2019 Results - Earnings Call Transcript

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 121.62% and 19.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Tops Q4 Earnings and Revenue Estimates

Company continues to execute on its international expansion strategy

Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

ATLANTA, Nov.  14, 2019  (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has filed a certificate of amendment to its restated certificate with the Secretary of State of the State of Delaware that will effect the previously announced one-for-15 reverse stock split of its common stock.  The certificate of amendment provides that the reverse stock split will become effective at 5:01 PM Eastern Time today, after the close of trading on The Nasdaq Global Market. On November 15, 2019, Alimera’s common stock will begin trading on a post-reverse stock split basis on The Nasdaq Global Market under the existing symbol “ALIM.”

Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

ATLANTA, Nov.  07, 2019  (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will effect a one-for-15 reverse stock split (reverse split) of its common stock that will become effective on November 14, 2019 after the close of trading on The Nasdaq Global Market. On November 15, 2019, Alimera’s common stock will begin trading on a post-reverse split basis on The Nasdaq Global Market under the existing symbol “ALIM.”

Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio

ATLANTA, Nov.  05, 2019  (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, and Phil Jones, the Company’s Chief Financial Officer, will participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York City on November 12, 2019.

Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

Alimera Sciences, Inc. (ALIM) CEO Richard Eiswirth on Q3 2019 Results - Earnings Call Transcript

Third Quarter and Recent Company Highlights:

Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update

ATLANTA, Oct.  25, 2019  (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has entered into a $20.0 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. 

Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital

Consolidated net revenue expected to exceed $12.8 million Consolidated net revenue expected to exceed $12.8 million

Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

ATLANTA, Sept.  05, 2019  (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that its board of directors has approved a proposal to effect a reverse stock split of its common stock. The reverse stock split is expected to result in a higher per share price and a corresponding lower number of total shares issued and outstanding, which should enable Alimera to attain the minimum $1.00 per share bid price requirement for its common stock as required for continued listing on the Nasdaq Global Market.

Alimera Sciences Board of Directors Approves Reverse Stock Split and  10b5-1 Stock Purchase Plan for U.S. Executive Management

Second country in Europe where patients now have access to this important new treatment option; marketing to commence immediately Second country in Europe where patients now have access to this important new treatment option; marketing to commence immediately

Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2019 Results - Earnings Call Transcript

Alimera Sciences has been struggling lately, but the selling pressure may be coming to an end soon.

Alimera Sciences Sees Hammer Chart Pattern: Time to Buy?

Alimera Sciences, Inc. (ALIM) CEO Dan Myers on Q1 2019 Results - Earnings Call Transcript

News for Alimera Sciences Stock (ALIM)